David Pelizzon Biography and Net Worth

Director of Alphatec


David R. Pelizzon serves as Director of the Company. Mr. Pelizzon was nominated pursuant to the Stockholders’ Agreement with Squadron Capital LLC. Mr. Pelizzon is the President of Squadron and a member of its Managing Committee, positions he has held since 2008. Prior to joining Squadron, Mr. Pelizzon was the Managing Director of Precision Edge Surgical Products Company from 2005 to 2008. Mr. Pelizzon is a retired U.S. Army officer who served nearly 30 years on active duty in airborne and special operations units. Mr. Pelizzon is a graduate of the U.S. Military Academy and earned advanced degrees from Harvard University and the U.S. Naval War College.

What is David R. Pelizzon's net worth?

The estimated net worth of David R. Pelizzon is at least $2.67 million as of May 10th, 2021. Mr. Pelizzon owns 268,837 shares of Alphatec stock worth more than $2,669,551 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Pelizzon may own. Learn More about David R. Pelizzon's net worth.

How do I contact David R. Pelizzon?

The corporate mailing address for Mr. Pelizzon and other Alphatec executives is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. Alphatec can also be reached via phone at (760) 431-9286 and via email at [email protected]. Learn More on David R. Pelizzon's contact information.

Has David R. Pelizzon been buying or selling shares of Alphatec?

David R. Pelizzon has not been actively trading shares of Alphatec during the last quarter. Most recently, on Thursday, November 11th, David R. Pelizzon bought 4,366 shares of Alphatec stock. The stock was acquired at an average cost of $11.41 per share, with a total value of $49,816.06. Learn More on David R. Pelizzon's trading history.

Who are Alphatec's active insiders?

Alphatec's insider roster includes Evan Bakst (Director), Jeffrey Black (CFO), Jason Hochberg (Director), Craig Hunsaker (EVP), Scott Lish (SVP), Patrick Miles (CEO), David Mowry (Director), David Pelizzon (Director), Jennifer Pritzker (Major Shareholder), Paul Segal (Major Shareholder), David Sponsel (EVP), and James Tullis (Director). Learn More on Alphatec's active insiders.

Are insiders buying or selling shares of Alphatec?

In the last twelve months, Alphatec insiders bought shares 3 times. They purchased a total of 85,000 shares worth more than $743,050.00. In the last twelve months, insiders at the medical technology company sold shares 12 times. They sold a total of 340,301 shares worth more than $4,593,019.43. The most recent insider tranaction occured on August, 21st when Director David M Demski bought 50,000 shares worth more than $283,500.00. Insiders at Alphatec own 22.8% of the company. Learn More about insider trades at Alphatec.

Information on this page was last updated on 8/21/2024.

David R. Pelizzon Insider Trading History at Alphatec

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Buy4,366$11.41$49,816.06View SEC Filing Icon  
11/8/2021Buy5,425$13.00$70,525.00View SEC Filing Icon  
5/10/2021Buy120,000$15.25$1,830,000.00268,837View SEC Filing Icon  
See Full Table

David R. Pelizzon Buying and Selling Activity at Alphatec

This chart shows David R Pelizzon's buying and selling at Alphatec by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alphatec Company Overview

Alphatec logo
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $9.93
Low: $9.82
High: $10.14

50 Day Range

MA: $6.52
Low: $4.98
High: $9.93

2 Week Range

Now: $9.93
Low: $4.88
High: $17.34

Volume

159,778 shs

Average Volume

1,957,064 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31